In diagnostics practice, an accurate MFC diagnosis of AMoL relies on the following steps: (i) negativity of B- (at least 2 among CD19, CD10, cyCD22, and cyCD79) or T-lineage (s/cyCD3 and CD7) acute lymphoblastic leukemia criteria; (ii) blasts assignment to the myeloid/monocytic lineage (positivity of at least 2 among MPO, CD13, CD33, CD64, CD65, CD117, cy-LYZO, CD14, CD11c); (iii) investigation of specific monocytic-lineage markers (CD11b, CD15, HLA-DR, CD371), (iv) hematopoietic stem cell marker (CD34), and (v) potential aberrant expression of CD7, CD56, CD19, cyCD79a, NG2 (1, 38, 71). Here, CD7 is linked to acute lymphoblastic leukemia.